BFRG Profile
BullFrog AI Holdings, Inc. is a digital biopharmaceutical company specializing in leveraging artificial intelligence and machine learning (AI/ML) for advanced data analysis in medicine and healthcare. Based in Gaithersburg, Maryland, BullFrog AI Holdings operates through its subsidiaries to develop cutting-edge solutions that integrate AI/ML technologies into the biopharmaceutical industry.
The company’s flagship product is bfLEAP, an AI/ML platform designed to analyze extensive preclinical and clinical datasets. This platform aims to enhance the efficiency and accuracy of drug development and clinical research by providing sophisticated tools for data interpretation and decision-making. By applying advanced machine learning algorithms, bfLEAP helps researchers and pharmaceutical companies gain deeper insights into complex biological data, ultimately accelerating the development of new therapies.
In addition to its proprietary technology, BullFrog AI Holdings holds licensing agreements with prominent research institutions. It has secured rights from George Washington University to utilize siRNA targeting Beta2-spectrin, focusing on the treatment of various human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis. The company also has an agreement with Johns Hopkins University to employ a formulation of Mebendazole for addressing human cancer and neoplastic diseases.
Founded in 2017, BullFrog AI Holdings is dedicated to innovating the biopharmaceutical landscape through its AI-driven approach. The company's integration of advanced technology with medical research aims to transform drug development and therapeutic discovery, positioning itself at the forefront of digital biopharma advancements.
|
